Validation of plasma proteomic biomarkers relating to brain amyloid burden in the EMIF-Alzheimer’s disease Multimodal Biomarker Discovery cohort

Manuscript Number: 

19-0434R3

Author(s): 
Sneha N. Anand, Nicholas J. Ashton, Alison L. Baird, Susan Baker, Frederik Barkhof, Lars Bertram, Olivier Blin, Régis Bordet, Isabelle Bos, Noel J. Buckley, Ellen De Roeck, Valerija Dobricic, Sebastiaan Engelborghs, Yvonne Freund-Levi, Giovanni B. Frisoni, Lutz Frölich, Silvy Gabel, Abdul Hye, Peter Johannsen, Petronella Kettunen, Andrey Kormilitzin, Cristina Legido-Quigley, Alberto Lleó, Simon Lovestone, Pablo Martínez-Lage, Karen Meersmans, José-Luis Molinuevo, Angharad R. Morgan, B. Paul Morgan, Alejo Nevado-Holgado, Gwendoline Peyratout, Julius Popp, Lorena Rami, Jill Richardson, Isabel Sala, Philip Scheltens, Liu Shi, Kristel Sleegers, Johannes Streffer, Mikel Tainta, Charlotte E. Teunissen, Magda Tsolaki, Rik Vandenberghe, Frans Verhey, Pieter Jelle Visser, Stephanie J.B. Vos, Anders Wallin, Sarah Westwood, Henrik Zetterberg, Mara ten Kate

Disclosures

Sneha N. Anand

  • Nothing to Disclose

Nicholas J. Ashton

  • Nothing to Disclose

Alison L. Baird

  • Nothing to Disclose

Susan Baker

  • Equity:
    Long Term Incentive Stock Options with Employer (J&J)

Frederik Barkhof

  • Consulting Fees:
    DSMB and Steering committee membership for Roche, Biogen, Merck, Bayer

Lars Bertram

  • Nothing to Disclose

Olivier Blin

  • Grants
    • Agency: 
      Innovative Medicine Initiative IMI sponsored project
      Dates: 
      2010-2016

Régis Bordet

  • Nothing to Disclose

Isabelle Bos

  • Nothing to Disclose

Noel J. Buckley

  • Nothing to Disclose

Ellen De Roeck

  • Nothing to Disclose

Valerija Dobricic

  • Nothing to Disclose

Sebastiaan Engelborghs

  • Consulting Fees:
    Consulting fees: Novartis, Nutricia, Eisai
    Grants
    • Agency: 
      Janssen Pharmaceutica and ADx Neurosciences
      Dates: 
      2015-2021

Yvonne Freund-Levi

  • Nothing to Disclose

Giovanni B. Frisoni

  • Nothing to Disclose

Lutz Frölich

  • Consulting Fees:
    consultancy fees from: Eli Lilly, Axon Neuroscience, Biogen, Boehringer Ingelheim, Eisai, Functional Neuromodulation, Lundbeck, MerckSharpe & Dohme, Novartis, Pharnext, Roche, Schwabe Pharma Data and Safety Monitoring boards or endpoint committees with: Avanir, Pharmatropix, Forschungszentrum Jülich, Neuroscios, Novartis
    Lecture Fees:
    Biogen, Eisai, Roche, Schwabe Pharma

Abdul Hye

  • Nothing to Disclose

Petronella Kettunen

  • Nothing to Disclose

Andrey Kormilitzin

  • Nothing to Disclose

Cristina Legido-Quigley

  • Nothing to Disclose

Alberto Lleó

  • Nothing to Disclose

Simon Lovestone

  • Consulting Fees:
    SL has performed consulting / advisory board tasks with payments of less than $3000 with the following companies in the past five years: SomaLogic Eisai Merck Optum Labs EIP pharma
    Patents/Royalties
    SL is named on patent applications and established IP for Biomarkers held by KCL and the University of Oxford
    Grants
    • Agency: 
      IMI (EMIF and EPAD) EU funding with multiple pharma companies in public private partnerships
      Dates: 
      2000-2019
    • Agency: 
      Astra Zeneca
      Dates: 
      2014-2019

Pablo Martínez-Lage

  • Nothing to Disclose

Karen Meersmans

  • Nothing to Disclose

José-Luis Molinuevo

  • Nothing to Disclose

Angharad R. Morgan

  • Nothing to Disclose

B. Paul Morgan

  • Consulting Fees:
    ad hoc advice and occasional advisory board attendance to RaPharma, Alexion, GSK and Roche. Fees and expenses paid in line with industry standard; for GSK and Roche these are paid to the University.
    Equity:
    Limited stock options in RaPharma; less than $50k
    Patents/Royalties
    Patents in the broad area of complement therapeutics

Alejo Nevado-Holgado

  • Equity:
    I own stock options of Akrivia Health (https://akriviahealth.com/), where I am the Chief of AI
    Grants
    • Agency: 
      Johnson and Johnson
      Dates: 
      2019-2022

Gwendoline Peyratout

  • Nothing to Disclose

Julius Popp

  • Consulting Fees:
    Consultant activity for Fujirebio Europe, related to commercially available Alzheimer's biomarkers, not related to the main subject of this study; fees payed to my institution (University of Lausanne, Switzerland) Consultant activity for Nestlé Institute of Health Sciences, Switzerland, related to a biomarker project, not related to the subject of this article; fees payed to my institution (University of Lausanne, Switzerland)

Lorena Rami

  • Nothing to Disclose

Jill Richardson

  • Equity:
    As an ex-employee I own GSK shares and also MSD shares now that I am a MSD employee

Isabel Sala

  • Nothing to Disclose

Philip Scheltens

  • Nothing to Disclose

Liu Shi

  • Nothing to Disclose

Kristel Sleegers

  • Nothing to Disclose

Johannes Streffer

  • Equity:
    UCB Biopharma SRL

Mikel Tainta

  • Nothing to Disclose

Mara ten Kate

  • Nothing to Disclose

Charlotte E. Teunissen

  • Consulting Fees:
    Roche.
    Lecture Fees:
    Biogen, Servier, Roche

Magda Tsolaki

  • Nothing to Disclose

Rik Vandenberghe

  • Patents/Royalties
    RV's institution has had clinical trial agreements (RV as PI) with GEHC as well as with Novartis, Roche, and Abbvie, and material transfer agreements with Avid Radiopharmaceuticals, a subsidiary of EliLilly.

Frans Verhey

  • Nothing to Disclose

Pieter Jelle Visser

  • Nothing to Disclose

Stephanie J.B. Vos

  • Nothing to Disclose

Anders Wallin

  • Nothing to Disclose

Sarah Westwood

  • Nothing to Disclose

Henrik Zetterberg

  • Consulting Fees:
    HZ has served at scientific advisory boards for Eli Lilly, Roche Diagnostics, Wave, CogRx and Samumed, has received travel support from Teva, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (all unrelated to this study).

Silvy Gabel

  • Disclosure not yet completed

Peter Johannsen

  • Disclosure not yet completed